Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosiglitazone - GlaxoSmithKline

Drug Profile

Rosiglitazone - GlaxoSmithKline

Alternative Names: Avandia; BRL 49653; BRL 49653C; Rosiglitazone extended-release; Rosiglitazone maleate; Rosiglitazone XR; RSG XR

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Bristol-Myers Squibb; GlaxoSmithKline
  • Class Antidementias; Antihyperglycaemics; Antipsoriatics; Small molecules; Thiazolidinediones
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Asthma
  • Discontinued Alzheimer's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Nov 2013 US FDA removes restrictions for use of rosiglitazone-containing drugs in Type 2 diabetes mellitus in the USA
  • 06 Jun 2013 Joint advisory committee to the FDA recommends that rosiglitazone remain available to appropriate patients in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top